Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...

Gilead Sciences said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical ...

Ferozsons Laboratories Limited (PSX: FEROZ) has entered into a non-exclusive voluntary license agreement with Gilead Sciences ...

Gilead Sciences has announced the signing of voluntary licencing agreements with six generic pharmaceutical manufacturers to ...

TEANECK, N.J., Oct. 16, 2024 /CNW/ -- Cognizant (NASDAQ:CTSH) today announced significant enhancements to its Cognizant Neuro ® AI platform, aimed at enabling enterprises to rapidly discover, ...

Future Financial Wealth Managment LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in ...

Gilead Sciences, Inc. (NASDAQ ... Moreover, Gilead will address new pre-exposure prophylaxis (PrEP) use in U.S. populations with unmet needs for HIV prevention. In COVID-19 research, Gilead ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir ...

Gilead Sciences Inc. has announced a new licensing deal to provide its twice-yearly experimental HIV prevention drug, lenacapavir, to six ...

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India ...

Gilead Sciences, Inc. has announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six ...